Stocks · News reference
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that an
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The New Mechanistic Findings Support Can-Fite’s Ongoing Phase IIb Study Design Following Positive Phase IIa ResultsRamat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF),
Read original at benzingaPhase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive resultsRamat Gan, Israel, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Can-Fite
Read original at benzingaCan-Fite BioPharma announced that its Phase 2a study results for Namodenoson in advanced pancreatic cancer patients have been accepted for poster presentation at ESMO Congress 2026. The study demonstrated durable disease stabilization and encouraging survival outcomes in third-line pancreatic cancer patients, with one patient remaining alive over 18 months after second-line treatment. The company plans to advance to a Phase 2b study combining Namodenoson with chemotherapy.
Read original at globenewswire-inc